Previous 10 | Next 10 |
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and clinical characteristics of ARIA-E, confirming proof...
2023-10-18 17:39:01 ET Gainers: Netflix ( NFLX ) +12% . Melco Resorts & Entertainment ( MLCO ) +5% . ADTRAN Holdings ( ADTN ) +4% . Acumen Pharmaceuticals ( ABOS ) +4% . Gracell Biotechnologies ( GRCL ) +4% . ...
Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included in a symposium on Friday, October 27 New data from additional exploratory analyses of...
2023-10-03 11:03:22 ET Summary Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show increased operating expenses and a net loss expansion, ...
2023-10-03 05:15:10 ET Summary Acumen Pharmaceuticals is developing a monoclonal antibody, ACU193, that targets Amyloid beta oligomers (AβOs) in Alzheimer's disease. AβOs are small, soluble aggregates of amyloid-beta peptides that are believed to be more toxic to neu...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, a...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, a...
2023-08-11 09:52:01 ET Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Conference Call August 08, 2023 08:00 AM ET Company Participants Alex Braun - Head-Investor Relations Dan O'Connell - Chief Executive Officer Eric Siemers - Chief Medical Officer Matt...
2023-08-08 07:43:40 ET Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q2 GAAP EPS of -$0.28 beats by $0.07 . As of June 30, 2023, cash, cash equivalents and marketable securities totaled $172.2 million, compared to cash, cash equivalents and marketable securiti...
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s disease Cash, cash equivalents and marketable securities of $172.2 million as of June 30, 2023, bolstered by ...
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalent...